Listen to an AI generated “Deep Dive” interview about this post.
What the Research Actually Shows (and What It Doesn’t)
If you’ve struggled with insomnia for years, chances are you’ve wondered: “Are my sleep medications harming my brain?” It’s a question I hear often, especially from thoughtful, health-conscious adults who are trying to make the best long-term decisions for themselves.
Before we go further, one important note: any changes to sleep medications should always be made in collaboration with your prescribing medical provider. Stopping or adjusting medications on your own can sometimes worsen sleep, increase anxiety, or lead to withdrawal effects. The goal here is not to create alarm—but to give you clear, balanced information so you can make informed decisions with your care team.
Let’s slow this down and look at what the science actually says. The information I talk about here is mostly based on a systematic review of the research published in 2024 (Chandramouleeshwaran S, et al. 2024; https://doi.org/10.1017/S1041610223000844).
The Big Picture: What Researchers Studied
A recent systematic review brought together decades of research examining how commonly prescribed psychiatric and sleep-related medications affect cognition in older adults over time. Rather than relying on short-term or anecdotal findings, the authors focused on studies that followed people over months and years, using validated cognitive tests to track changes over time.
Across 27 studies, researchers looked at medications many people with chronic insomnia are familiar with—benzodiazepines, antidepressants (including medications like trazodone), antipsychotics, and combinations of these drugs. Importantly, these studies included individuals both with and without cognitive impairment at baseline, which helps us understand how these medications may affect different populations. What emerges is not a simple “good” or “bad” answer, but a more nuanced picture of risk, context, and individual differences.
Benzodiazepines: Small but Meaningful Risks Over Time
When it comes to benzodiazepines, the research does suggest an association with cognitive decline—but the details matter. Studies consistently show that long-term and cumulative use is where the risk becomes clearer. People who take these medications regularly over extended periods, especially longer-acting versions, tend to show subtle declines on cognitive testing over time.
At the same time, the size of this effect is generally small in many studies, and not all studies find the same results. One complicating factor is that benzodiazepines are sometimes prescribed for symptoms—like anxiety, agitation, or sleep disruption—that can themselves be early signs of cognitive decline. In those cases, it can look like the medication caused the problem, when in fact it may have been part of an early response to it.
Taken together, the most correct conclusion is this: there is a signal of risk, particularly with long-term, habitual use—but it is not large, not universal, and not inevitable.
Antidepressants: A More Complicated Story
The relationship between antidepressants and cognition is less straightforward. Some studies show an increased risk of mild cognitive impairment or dementia, while others show no effect—or even slower cognitive decline in certain groups. This inconsistency reflects something important: antidepressants are not a single category, and the people taking them are not a uniform group.
One clearer finding is that medications with anticholinergic properties, such as paroxetine and some older antidepressants (such as amitriptyline and imipramine), are more consistently associated with negative cognitive effects. These medications can interfere with neurotransmitter systems that are important for memory and attention, particularly in older adults.
However, there’s a critical layer beneath all of this: depression itself is a known risk factor for cognitive decline and dementia. This makes it difficult to separate the effects of the medication from the effects of the condition being treated. In some cases, effective treatment of depression may actually support cognitive health, while in others the medication may contribute modestly to decline. The reality is often a mix of both.
Trazodone: A Notable Exception Worth Understanding
One of the more interesting findings in this review involves trazodone, a medication often used for sleep. In at least one study, individuals taking trazodone showed slower rates of cognitive decline, particularly if they had sleep disturbances at baseline.
This may relate to trazodone’s ability to enhance slow-wave sleep, the deeper stages of sleep that are believed to support memory consolidation and brain restoration. While this doesn’t mean trazodone is protective in a broad sense, it does highlight an important point: not all sleep medications carry the same cognitive risk profile, and some may interact with brain health in more complex—and sometimes beneficial—ways.
Antipsychotics: Clearer Signals of Cognitive Impact
Among the medication classes studied, antipsychotics showed the most consistent association with cognitive decline. In several studies, the rate of decline was more pronounced and clinically meaningful compared to other medication types.
It’s important to understand the context, though. These medications are typically prescribed for more severe symptoms, such as agitation or psychosis, often in individuals who already have some degree of cognitive impairment. Even so, the findings suggest that these medications can contribute to further decline, which is why their use in older adults is generally approached with caution and ongoing monitoring.
A Critical Reality Check: What These Studies Can—and Can’t—Tell Us
As compelling as these findings are, they come with important limitations. Most of the studies in this review were observational, meaning they can find patterns and associations but cannot prove direct cause and effect. This leaves room for reverse causation, where early cognitive changes lead to medication use, rather than the other way around.
Additionally, factors like underlying mental health conditions, sleep problems, and overall health status all influence cognitive outcomes. Medications are just one piece of a much larger puzzle. So, while it is reasonable to take these findings seriously, it is equally important not to overinterpret them or assume inevitability.
The Other Side of the Equation: The Risks of Untreated Insomnia
One of the most important—and often overlooked—parts of this conversation is what happens when insomnia is left untreated. Chronic insomnia is not simply an inconvenience; it is associated with increased risk of depression, anxiety, impaired daytime functioning, and even cognitive difficulties over time.
For many people, sleep medications provide meaningful relief, especially in difficult periods. They can reduce suffering, improve functioning, and create a bridge toward more stable sleep. So, the goal is not to eliminate medications at all costs, but to understand their role within a broader, long-term plan.
The Role of CBT-I: What Guidelines Recommend
Because of these complexities, multiple major organizations recommend Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment. CBT-I addresses the underlying patterns that keep insomnia going, rather than simply managing symptoms. It has been shown to produce durable improvements in sleep without the side effects associated with medications. For many people, it also creates a pathway to reduce or stop medications safely, when appropriate.
A Balanced Way to Think About Medications and Brain Health
When you step back and look at the full picture, a more balanced perspective begins to emerge. Sleep medications are neither harmless nor inherently dangerous. Their risks tend to be dose-dependent, time-dependent, and context-dependent, and for most people those risks are modest rather than catastrophic.
At the same time, staying stuck in a long-term pattern of poor sleep and heavy reliance on medication—without addressing the underlying drivers of insomnia—may carry its own costs. The most effective approach is often not “either/or,” but thoughtful integration: using medications when helpful, while building skills and strategies that support long-term sleep and brain health.
What if You Are Dependent on Sleep Medications?
If you’ve been taking a sleep medication for a long time, it’s very common to feel stuck—and sometimes scared. Many people worry that they’ve become dependent on something that may not be helping them anymore, or worse, might be harming them over time. That fear can create a difficult bind: continuing the medication feels uncomfortable, but stopping it feels overwhelming or even impossible.
There is good news here. Many people—even those with long-standing insomnia—can learn to sleep well again without relying on medication. This doesn’t typically happen overnight, and it’s rarely about simply “stopping” a medication. Instead, it involves building new sleep patterns while gradually and safely reducing reliance on medication in a structured, supported way.
One approach we use is called blinded tapering, which combines principles from CBT-I with a carefully managed reduction in medication where dose changes are not consciously tracked day-to-day. This can help reduce the anxiety and fear that often make stopping sleep medication so difficult. If you’re curious about this approach, read our guide Breaking Free from Sleep Medication: Blinded Tapering + CBT-I
The key idea is this: you don’t have to choose between staying stuck on medication and going it alone. There are structured, evidence-informed ways to move forward.
The Takeaway
If you’re concerned about how sleep medications may affect your cognition, you’re asking an important and worthwhile question. The research suggests there are real risks to be aware of—but also that those risks are nuanced, variable, and often smaller than people fear.
Rather than reacting out of concern or urgency, the most helpful next step is to become informed, thoughtful, and collaborative in your approach. That means understanding your options, considering both the risks of medication and the risks of untreated insomnia, and working toward a plan that supports your long-term well-being.
If you’re looking for a partner in taking an informed, thoughtful, and collaborative approach to insomnia and sleep medications, you’re not alone. Collaborating with a specialist who understands both the science of sleep and the realities of long-term medication use can make a meaningful difference.
At our clinic, we work with individuals who want to better understand their sleep, reduce reliance on medications when appropriate, and build a sustainable path forward. If that sounds like what you’re looking for, we invite you to schedule a consultation with an insomnia specialist.
And one final reminder: if you’re considering reducing or stopping sleep medication, do so in partnership with your prescribing medical provider. A gradual, well-supported plan is far more likely to succeed—and far less likely to create new problems—than trying to figure it out on your own.
FAQ: Sleep Medications, Dementia, and Insomnia
Do sleep medications cause dementia?
Current research shows an association in some cases—especially with long-term benzodiazepine use—but not proof that these medications directly cause dementia. The risk appears modest and depends on duration, dose, and individual factors.
Which sleep medications are most concerning for cognition?
Long-term benzodiazepine use and medications with strong anticholinergic effects (e.g., some older antidepressants) have the most consistent links with cognitive changes.
Is it safer to stop sleep medication immediately?
No. Abrupt discontinuation can worsen insomnia and cause withdrawal symptoms. Any changes should be made in collaboration with a prescribing medical provider.
What is the safest long-term treatment for insomnia?
Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as first-line treatment by major medical organizations and has durable benefits without medication-related risks.
